-
Most Recent
Search Results
240 results for MER
5 Plays 3M’s New CEO Must Run to Win
As CEO Buckley hands over the reins, the stakes are high for 3M to get this changing of the guard right.
New GERM ETF Debuts at Just the Right Time
The race for a Covid-19 vaccine will bring eyes to the new GERM ETF, but there’s long-term available here, too.
Gilead Stock Flies High With a Potential Coronavirus Treatment
GILD stock could skyrocket if it is first in the door to provide an effective treatment for the coronavirus with its remdesivir drug.
Gilead’s Coronavirus Drug Could Propel GILD Stock Much Higher
Gilead’s coronavirus drug could propel GILD stock much higher. If Gilead’s coronavirus drug remdesivir has successful trials, GILD stock could skyrocket.
Which China ETF is Right For You?
The best way to get exposure to China’s value is through exchange-traded funds. Here are three China ETFs investors should consider picking up.
An Investor’s Guide to Housing’s Courtroom Dramas
Lawsuits are joining jobs and the economy as a major weight on housing. Here are some key legal issues investors need to monitor.
Opportunity Knocks: 3 Large-Cap Stocks to Buy at 52-Week Lows
Uncover investment opportunities with these large-cap stocks at 52-week lows. See why these beaten-down giants are set for a strong recovery.
The Song Remains the Same
Despite Thursday’s reversals, nothing has changed the major trend of the market.
CCL Stock Is Staring at a Very Bleak Future
Due to coronavirus fears causing major disruptions to the cruise liner industry, CCL stock naturally suffered huge losses. But the volatility may not be over…
Slicing Through the Election Rhetoric
We’re a stone’s throw away from the November elections, and both John McCain and Barack Obama have upped the rhetoric about the state of the…
Novavax Stock Got Merck-ed, but Don’t Dump Your Shares Now
NVAX stock still has plenty of value as Novavax has a rich and diverse clinical pipeline, including a promising influenza vaccine candidate.
Novavax Stock Is Poised to Climb Further
NVAX stock seems positioned for further gains with the firm’s vaccine deliveries set to begin in early 2022.
Novavax: Big Market Potential, Meaningful Stock Upside
Even after a 5,690% gain, NVAX stock looks positioned for further upside with the firm’s focus on bringing vaccines to low-income countries.
Inovio Pharma’s Next Clinical Results Will be Binary for INO Stock
Inovio Pharma’s next clinical results will be a binary event for INO Stock. It will rise or fall based on its Phase 1 results due…
Add Inovio Stock to Your High-Growth Biotech Holdings
You can call INO a coronavirus stock, but it’s really much more than that.
Inovio Is Still Hot as the Coronavirus Spreads
INO stock still has some serious upside, thanks to its INO-4800. Inovio’s coronavirus vaccine takes the lead and is in preclinical trials.
Gilead’s Cash and the Coronavirus Make GILD Stock Look Cheap
Gilead Sciences rose to prominence with its hepatitis C drug. Now GILD stock is soaring on hopes for a coronavirus treatment.
Focus on iBio’s Tech, Not Its Coronavirus Story
IBIO stock shot up in March on news that it might produce a coronavirus vaccine. However, its at-scale production tech is more interesting.
iBio Stock Is Too Risky
IBIO stock gets attention because of iBio’s foray into treating the coronavirus, but investors who want that exposure should look elsewhere.
Don’t Buy Inovio Stock on Hopes for a Vaccine
Coronavirus hysteria on Wall Street is temporary. When it passes, INO stock could turn into a “look out below” situation.
Bet on INO Stock Beyond Its Promising Covid-19 Vaccine Developments
Inovio just launched its Phase 1 trials of INO-4800 for a vaccine. Should all go according to plan, INO could run to at least $20…
Gilead Sciences Pins Its Hopes on Remdesivir
Clinical trial results for Gilead’s remdesivir should come this month. If it’s effective, GILD stock could explode higher on the news.
5 – 10 of 240 results
